Pub Date : 2005-07-31DOI: 10.2174/1568014054546263
F. Murphy, K. Keating, D. Sheehan, I. Hayes
{"title":"Immunological Approaches to Prevent Neuronal Apoptosis During Neuroinflammation","authors":"F. Murphy, K. Keating, D. Sheehan, I. Hayes","doi":"10.2174/1568014054546263","DOIUrl":"https://doi.org/10.2174/1568014054546263","url":null,"abstract":"","PeriodicalId":88233,"journal":{"name":"Current medicinal chemistry. Anti-inflammatory & anti-allergy agents","volume":"4 1","pages":"367-381"},"PeriodicalIF":0.0,"publicationDate":"2005-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1568014054546263","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67902134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2005-05-31DOI: 10.2174/1568014054065186
R. Q. L. A. J. M. Trzaskos
{"title":"Aggrecanase: The Family and Its Inhibitors","authors":"R. Q. L. A. J. M. Trzaskos","doi":"10.2174/1568014054065186","DOIUrl":"https://doi.org/10.2174/1568014054065186","url":null,"abstract":"","PeriodicalId":88233,"journal":{"name":"Current medicinal chemistry. Anti-inflammatory & anti-allergy agents","volume":"4 1","pages":"251-264"},"PeriodicalIF":0.0,"publicationDate":"2005-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1568014054065186","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67902317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2005-05-31DOI: 10.2174/1568014054065267
Frederick L. Makrauer and Robert Burakoff
{"title":"Biologic and Novel Therapy of the Inflammatory Bowel Diseases","authors":"Frederick L. Makrauer and Robert Burakoff","doi":"10.2174/1568014054065267","DOIUrl":"https://doi.org/10.2174/1568014054065267","url":null,"abstract":"","PeriodicalId":88233,"journal":{"name":"Current medicinal chemistry. Anti-inflammatory & anti-allergy agents","volume":"4 1","pages":"319-331"},"PeriodicalIF":0.0,"publicationDate":"2005-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1568014054065267","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67902521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2005-05-31DOI: 10.2174/1568014054065195
J. Haddad, N. Saadé, B. Safieh‐Garabedian
Thymulin is a neuroendocrine hormone with immunoregulatory actions. Originally known as 'serum thymic factor' (FTS), thymulin binds to a carrier protein and zinc (Zn2+) to exert its biologic properties. Thymulin, albeit an es- sential hormone for the T lymphocyte differentiation and the normalization of the ratio of T-helper cells to suppressor cells, accumulating evidence suggests its involvement in inflammations of various etiologies. Recently, thymulin has been shown to have anti-nociceptive effects in hyperalgesia and in pain of neurogenic origin, ostensibly through action on sen- sory afferents and the release of anti-inflammatory mediators. Given its anti-inflammatory potential, thymulin downregu- lates the release of inflammatory mediators, such as cytokines and chemokines, upregulates anti-inflammatory factors, such as interleukin (IL)-10, and exerts molecular control via the regulation of transcription factors and mediators. Recent evidence tends to indicate that thymulin can be a therapeutic agent in many inflammatory diseases and in pathological conditions affecting the peripheral and/or the central nervous system. This review discusses current concepts in the anti- inflammatory actions of thymulin and correlates this activity with an emerging theme for therapeutic treatment.
{"title":"Thymulin: An Emerging Anti-Inflammatory Molecule","authors":"J. Haddad, N. Saadé, B. Safieh‐Garabedian","doi":"10.2174/1568014054065195","DOIUrl":"https://doi.org/10.2174/1568014054065195","url":null,"abstract":"Thymulin is a neuroendocrine hormone with immunoregulatory actions. Originally known as 'serum thymic factor' (FTS), thymulin binds to a carrier protein and zinc (Zn2+) to exert its biologic properties. Thymulin, albeit an es- sential hormone for the T lymphocyte differentiation and the normalization of the ratio of T-helper cells to suppressor cells, accumulating evidence suggests its involvement in inflammations of various etiologies. Recently, thymulin has been shown to have anti-nociceptive effects in hyperalgesia and in pain of neurogenic origin, ostensibly through action on sen- sory afferents and the release of anti-inflammatory mediators. Given its anti-inflammatory potential, thymulin downregu- lates the release of inflammatory mediators, such as cytokines and chemokines, upregulates anti-inflammatory factors, such as interleukin (IL)-10, and exerts molecular control via the regulation of transcription factors and mediators. Recent evidence tends to indicate that thymulin can be a therapeutic agent in many inflammatory diseases and in pathological conditions affecting the peripheral and/or the central nervous system. This review discusses current concepts in the anti- inflammatory actions of thymulin and correlates this activity with an emerging theme for therapeutic treatment.","PeriodicalId":88233,"journal":{"name":"Current medicinal chemistry. Anti-inflammatory & anti-allergy agents","volume":"86 1","pages":"333-338"},"PeriodicalIF":0.0,"publicationDate":"2005-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1568014054065195","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67902330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2005-05-31DOI: 10.2174/1568014054065221
L. Lohmander
Osteoarthritis (sometimes called “arthrosis” or “osteoarthrosis”) often entails a slow and gradual deterioration of the joint that may sometimes lead to its total destruction and the need for an operation to replace it. However, for most patients with osteoarthritis, surgical treatment never becomes necessary, and their symptoms can be dealt with satisfactorily by self management, by non-pharmacological treatment or by pharmacological treatment. Osteoarthritis is not one single disease, but should rather be seen as a common final stage, joint failure, where the initial stages of the disease process can be triggered by many different causes. The main symptoms are joint pain, stiffness and limited mobility, which may lead to impairment and handicap. When the disease is far advanced an X-ray examination will show signs in the form of reduced joint space and osteophytes. These changes to the structure of the joint are caused by the destruction of the articular cartilage and the growth of bone deposits at the margins of the joints. Today there is no treatment which can stop the progress of the arthritic disease and joint destruction in osteoarthritis, but there is a series of treatments which can reduce the pain and help to maintain or improve function. (Less)
{"title":"Osteoarthritis - An Update","authors":"L. Lohmander","doi":"10.2174/1568014054065221","DOIUrl":"https://doi.org/10.2174/1568014054065221","url":null,"abstract":"Osteoarthritis (sometimes called “arthrosis” or “osteoarthrosis”) often entails a slow and gradual deterioration of the joint that may sometimes lead to its total destruction and the need for an operation to replace it. However, for most patients with osteoarthritis, surgical treatment never becomes necessary, and their symptoms can be dealt with satisfactorily by self management, by non-pharmacological treatment or by pharmacological treatment. Osteoarthritis is not one single disease, but should rather be seen as a common final stage, joint failure, where the initial stages of the disease process can be triggered by many different causes. The main symptoms are joint pain, stiffness and limited mobility, which may lead to impairment and handicap. When the disease is far advanced an X-ray examination will show signs in the form of reduced joint space and osteophytes. These changes to the structure of the joint are caused by the destruction of the articular cartilage and the growth of bone deposits at the margins of the joints. Today there is no treatment which can stop the progress of the arthritic disease and joint destruction in osteoarthritis, but there is a series of treatments which can reduce the pain and help to maintain or improve function. (Less)","PeriodicalId":88233,"journal":{"name":"Current medicinal chemistry. Anti-inflammatory & anti-allergy agents","volume":"4 1","pages":"209-215"},"PeriodicalIF":0.0,"publicationDate":"2005-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1568014054065221","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67902430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2005-05-31DOI: 10.2174/1568014054065203
K. Gelse, T. Aigner, J. Stove, H. Schneider
{"title":"Gene Therapy Approaches for Cartilage Injury and Osteoarthritis","authors":"K. Gelse, T. Aigner, J. Stove, H. Schneider","doi":"10.2174/1568014054065203","DOIUrl":"https://doi.org/10.2174/1568014054065203","url":null,"abstract":"","PeriodicalId":88233,"journal":{"name":"Current medicinal chemistry. Anti-inflammatory & anti-allergy agents","volume":"4 1","pages":"265-279"},"PeriodicalIF":0.0,"publicationDate":"2005-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1568014054065203","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67902345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2005-05-31DOI: 10.2174/1568014054065258
H. Skouri, P. Zalloua, A. Abchee
{"title":"Inflammation in Atherosclerosis: A New Therapeutic Target","authors":"H. Skouri, P. Zalloua, A. Abchee","doi":"10.2174/1568014054065258","DOIUrl":"https://doi.org/10.2174/1568014054065258","url":null,"abstract":"","PeriodicalId":88233,"journal":{"name":"Current medicinal chemistry. Anti-inflammatory & anti-allergy agents","volume":"4 1","pages":"283-295"},"PeriodicalIF":0.0,"publicationDate":"2005-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1568014054065258","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67902504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2005-05-31DOI: 10.2174/1568014054065285
J. Martel-Pelletier, G. Tardif, S. Laufer, J. Pelletier
{"title":"Cytokines and Growth Factors in the Treatment of Osteoarthritis: What Could be the Best Disease Modifying Drugs","authors":"J. Martel-Pelletier, G. Tardif, S. Laufer, J. Pelletier","doi":"10.2174/1568014054065285","DOIUrl":"https://doi.org/10.2174/1568014054065285","url":null,"abstract":"","PeriodicalId":88233,"journal":{"name":"Current medicinal chemistry. Anti-inflammatory & anti-allergy agents","volume":"97 1","pages":"235-249"},"PeriodicalIF":0.0,"publicationDate":"2005-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1568014054065285","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67902563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：